Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

International Randomised Controlled Trial for the Treatment of Newly Diagnosed Ewing's Sarcoma Family of Tumours

Next Previous
X
Search
Trial Profile

International Randomised Controlled Trial for the Treatment of Newly Diagnosed Ewing's Sarcoma Family of Tumours

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zoledronic acid (Primary) ; Autologous stem cell therapy; Busulfan; Cyclophosphamide; Dactinomycin; Doxorubicin; Etoposide; Ifosfamide; Melphalan; Vincristine
  • Indications Ewing's sarcoma
  • Focus Therapeutic Use
  • Acronyms EE2012; Euro Ewing 2012

    • Most Recent Events

    • 18 Apr 2024 Planned End Date changed from 30 Apr 2024 to 1 Sep 2024.
    • 15 Jul 2022 Patient recruitment was completed on 30 Apr 2019
    • 31 May 2020 Results of overall and subgroup analysis from EE2012 trial presented at the 56th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top